`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`BRISTOL-MYERS SQUIBB COMP ANY and
`PFIZER INC.,
`
`Plain tiffs and Counterclaim-Defendants
`
`V.
`
`AUROBINDO PHARMA USA INC. and
`AUROBINDO PHARMA LTD.,
`
`Defendants and Counterclaim-Plaintiffs.
`
`BRISTOL-MYERS SQUIBB COMPANY
`and PFIZER INC.,
`
`Plaintiffs,
`
`V.
`
`MYLAN PHARMACEUTICALS INC.,
`
`Defendant.
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`At Wilmington, this 18th day of October, 2018:
`
`ORDER
`
`C.A. No. 17-374-LPS
`(CONSOLIDATED)
`
`C.A. No. 17-379-LPS
`
`For the reasons set forth in the Memorandum Opinion issued on this date,
`
`IT IS HEREBY ORDERED that Defendant Mylan Pharmaceuticals Inc.'s Motion to
`
`Dismiss or Transfer Under 28 U.S.C. § 1406(a) for Improper Venue (C.A. No. 17-379 D.I. 178)
`
`is GRANTED. IT IS FURTHER ORDERED that the parties shall meet and confer and, no
`
`later than October 22, 2018, submit a joint status report and any necessary or requested order to
`
`implement today's decision.
`
`TATES DIS
`
`E
`
`